Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash & Equivalents (2016 - 2025)

Rocket Pharmaceuticals' Cash & Equivalents history spans 10 years, with the latest figure at $188.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 15.44% year-over-year to $188.9 million; the TTM value through Dec 2025 reached $188.9 million, up 15.44%, while the annual FY2025 figure was $188.9 million, 15.44% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $188.9 million at Rocket Pharmaceuticals, up from $75.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $466.4 million in Q1 2021 and bottomed at $32.8 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $210.8 million (2021), against an average of $214.6 million.
  • The largest annual shift saw Cash & Equivalents soared 192.71% in 2024 before it crashed 88.23% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $232.7 million in 2021, then plummeted by 39.61% to $140.5 million in 2022, then tumbled by 60.22% to $55.9 million in 2023, then skyrocketed by 192.71% to $163.6 million in 2024, then rose by 15.44% to $188.9 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Cash & Equivalents are $188.9 million (Q4 2025), $75.9 million (Q3 2025), and $32.8 million (Q2 2025).